Year-to-date, Amarin (AMRN) stock is up nearly 20% due to Pfizer buyout chatter. According to rumors, the pharma giant is interested in making …

Send ResMed (RMD) shares tanked nearly 18% today, leaving investors at odds over when it will hit a bottom. What’s causing investors to hit …

TherapeuticsMD (TXMD) investors are keeping an eye on the pace of commercialization efforts for Imvexxy, Annovera, and Bijuva. That will prove critical for …

A lot of Amarin (AMRN) stock bulls expected shares to fly up toward $30 following shockingly good results of the company’s Reduce-It cardiovascular …

Wednesday turned out to be a nightmare for Aptinyx (APTX) investors, as the stock price crashed nearly 70% in the wake of clinical …

Amarin (AMRN) has been Wall Street’s biggest standout of 2018, with shares skyrocketing nearly 240%. The biggest question for investors, then, is whether …

Axsome Therapeutics (AXSM) stock more than doubled since the drug maker announced positive results for its phase 2 trial, ASCEND on Monday. The …

La Jolla’s (LJPC) shares lost almost half of their value Monday, after the company pre-announced fourth quarter revenues for its drug Giapreza – …

Aphria (APHA) stock has been experiencing some turbulence ever since a short report came out in early December suggesting the company was benefiting …

Bausch Health (BHC) is getting a bit of special treatment. Following a tough run of negative sentiment toward the company, Piper Jaffray analyst David Amsellem …